BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 15104675)

  • 1. Promyelocytic leukemia (PML) nuclear bodies are disorganized in colorectal tumors with total loss of major histocompatibility complex class I expression and LMP7 downregulation.
    Cabrera CM; Jiménez P; Concha A; Garrido F; Ruiz-Cabello F
    Tissue Antigens; 2004 May; 63(5):446-52. PubMed ID: 15104675
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interferon gamma regulates accumulation of the proteasome activator PA28 and immunoproteasomes at nuclear PML bodies.
    Fabunmi RP; Wigley WC; Thomas PJ; DeMartino GN
    J Cell Sci; 2001 Jan; 114(Pt 1):29-36. PubMed ID: 11112687
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PML and TRF2 protein expression in hereditary and sporadic colon cancer.
    Plevová P; Bouchal J; Fiurásková M; Papezová M; Krepelová A; Curík R; Foretová L; Navrátilová M; Zapletalová J; Posolda T; Kolár Z
    Neoplasma; 2007; 54(4):269-77. PubMed ID: 17822315
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Arsenic degrades PML or PML-RARalpha through a SUMO-triggered RNF4/ubiquitin-mediated pathway.
    Lallemand-Breitenbach V; Jeanne M; Benhenda S; Nasr R; Lei M; Peres L; Zhou J; Zhu J; Raught B; de Thé H
    Nat Cell Biol; 2008 May; 10(5):547-55. PubMed ID: 18408733
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Heterogeneous nuclear expression of the promyelocytic leukemia (PML) protein in normal and neoplastic human tissues.
    Gambacorta M; Flenghi L; Fagioli M; Pileri S; Leoncini L; Bigerna B; Pacini R; Tanci LN; Pasqualucci L; Ascani S; Mencarelli A; Liso A; Pelicci PG; Falini B
    Am J Pathol; 1996 Dec; 149(6):2023-35. PubMed ID: 8952536
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Knocking down PML impairs p53 signaling transduction pathway and suppresses irradiation induced apoptosis in breast carcinoma cell MCF-7.
    Bao-Lei T; Zhu-Zhong M; Yi S; Jun-Jie Q; Yan D; Hua L; Bin L; Guo-Wei Z; Zhi-Xian S
    J Cell Biochem; 2006 Feb; 97(3):561-71. PubMed ID: 16215989
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Concordant expression of proto-oncogene promyelocytic leukemia and major histocompatibility antigen HLA class I in human hepatocellular carcinoma.
    Xia M; Zhang JQ; Shen YQ; Xu LH; Chen AQ; Miao FQ; Xie W
    Tissue Antigens; 2007 Oct; 70(4):272-82. PubMed ID: 17767548
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Promyelocytic leukemia protein is redistributed during the formation of intranuclear inclusions independent of polyglutamine expansion: an immunohistochemical study on Marinesco bodies.
    Kumada S; Uchihara T; Hayashi M; Nakamura A; Kikuchi E; Mizutani T; Oda M
    J Neuropathol Exp Neurol; 2002 Nov; 61(11):984-91. PubMed ID: 12430715
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Arsenic-induced SUMO-dependent recruitment of RNF4 into PML nuclear bodies.
    Geoffroy MC; Jaffray EG; Walker KJ; Hay RT
    Mol Biol Cell; 2010 Dec; 21(23):4227-39. PubMed ID: 20943951
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Triterpenoid CDDO-Im downregulates PML/RARalpha expression in acute promyelocytic leukemia cells.
    Ikeda T; Kimura F; Nakata Y; Sato K; Ogura K; Motoyoshi K; Sporn M; Kufe D
    Cell Death Differ; 2005 May; 12(5):523-31. PubMed ID: 15746941
    [TBL] [Abstract][Full Text] [Related]  

  • 11. β-catenin inhibits promyelocytic leukemia protein tumor suppressor function in colorectal cancer cells.
    Satow R; Shitashige M; Jigami T; Fukami K; Honda K; Kitabayashi I; Yamada T
    Gastroenterology; 2012 Mar; 142(3):572-81. PubMed ID: 22155184
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Promyelocytic leukemia nuclear bodies provide a scaffold for human polyomavirus JC replication and are disrupted after development of viral inclusions in progressive multifocal leukoencephalopathy.
    Shishido-Hara Y; Higuchi K; Ohara S; Duyckaerts C; Hauw JJ; Uchihara T
    J Neuropathol Exp Neurol; 2008 Apr; 67(4):299-308. PubMed ID: 18379438
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RNF4 is a poly-SUMO-specific E3 ubiquitin ligase required for arsenic-induced PML degradation.
    Tatham MH; Geoffroy MC; Shen L; Plechanovova A; Hattersley N; Jaffray EG; Palvimo JJ; Hay RT
    Nat Cell Biol; 2008 May; 10(5):538-46. PubMed ID: 18408734
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proteasome-dependent dispersal of PML nuclear bodies in response to alkylating DNA damage.
    Conlan LA; McNees CJ; Heierhorst J
    Oncogene; 2004 Jan; 23(1):307-10. PubMed ID: 14712236
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Concordant down-regulation of proto-oncogene PML and major histocompatibility antigen HLA class I expression in high-grade prostate cancer.
    Zhang H; Melamed J; Wei P; Cox K; Frankel W; Bahnson RR; Robinson N; Pyka R; Liu Y; Zheng P
    Cancer Immun; 2003 Feb; 3():2. PubMed ID: 12747744
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Conjugation with the ubiquitin-related modifier SUMO-1 regulates the partitioning of PML within the nucleus.
    Müller S; Matunis MJ; Dejean A
    EMBO J; 1998 Jan; 17(1):61-70. PubMed ID: 9427741
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proteasome-independent disruption of PML oncogenic domains (PODs), but not covalent modification by SUMO-1, is required for human cytomegalovirus immediate-early protein IE1 to inhibit PML-mediated transcriptional repression.
    Xu Y; Ahn JH; Cheng M; apRhys CM; Chiou CJ; Zong J; Matunis MJ; Hayward GS
    J Virol; 2001 Nov; 75(22):10683-95. PubMed ID: 11602710
    [TBL] [Abstract][Full Text] [Related]  

  • 18. cAMP signalling is decisive for recovery of nuclear bodies (PODs) during maturation of RA-resistant t(15;17) promyelocytic leukemia NB4 cells expressing PML-RAR alpha.
    Duprez E; Lillehaug JR; Naoe T; Lanotte M
    Oncogene; 1996 Jun; 12(11):2451-9. PubMed ID: 8649787
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proteins associated with the promyelocytic leukemia gene product (PML)-containing nuclear body move to the nucleolus upon inhibition of proteasome-dependent protein degradation.
    Mattsson K; Pokrovskaja K; Kiss C; Klein G; Szekely L
    Proc Natl Acad Sci U S A; 2001 Jan; 98(3):1012-7. PubMed ID: 11158586
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ZNF198, a zinc finger protein rearranged in myeloproliferative disease, localizes to the PML nuclear bodies and interacts with SUMO-1 and PML.
    Kunapuli P; Kasyapa CS; Chin SF; Caldas C; Cowell JK
    Exp Cell Res; 2006 Nov; 312(19):3739-51. PubMed ID: 17027752
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.